Dyne Therapeutics reports positive results from trials and completes public offering to support pipeline

From GlobeNewswire: 2024-08-12 17:10:00

Dyne Therapeutics, Inc. reported positive results from the ACHIEVE Trial of DYNE-101 in DM1 and the DELIVER Trial of DYNE-251 in DMD. The trials showed significant improvement in key biomarkers and functional endpoints. Dyne also completed a $374 million public offering to support their innovative pipeline. Cash reserves are expected to last until at least the second half of 2026.

In the ACHIEVE Trial, DYNE-101 demonstrated muscle delivery, splicing correction, and improvements in myotonia, muscle strength, and functional tests in DM1 patients. Safety data confirmed a favorable profile. In the DELIVER Trial, DYNE-251 showed dose-dependent exon skipping and dystrophin expression in DMD patients. The trials aim at an expedited approval pathway with the FDA.

Dyne plans to engage with global regulators to discuss the path to registration for DYNE-101 and DYNE-251 by the end of 2024. The FORCE™ platform showcased potential benefits for FSHD and Pompe disease models. The company also submitted data from ongoing trials for presentation at upcoming conferences.

With a cash position of $778.8 million as of June 30, 2024, Dyne is well-funded for operations until at least the second half of 2026. Research and development expenses for the second quarter were $62.3 million, supporting the progress of their clinical programs. The company aims to provide updates on their pipeline programs in the future.



Read more at GlobeNewswire:: Dyne Therapeutics Reports Second Quarter 2024 Financial